Introducing Nature Cancer
Watch our Chief Editor introduce Nature Cancer in this video.
Aims & scope
Nature Cancer aims to publish the most significant advances across the full spectrum of cancer research in the life, physical, applied and social sciences, spanning basic preclinical, translational and clinical work. The journal’s broad scope covers all cancer research offering new insights into cancer biology and genetics, new approaches for the development and delivery of diagnostics and therapies, and new ways of understanding the global societal impact of cancer, ensuring that the work published reaches the widest possible audience. For more information please see Aims & Scope.
Nature Cancer is an exclusively online publication. Research articles will be published as soon as they are ready, benefiting authors with the earliest possible publication date and allowing our readers access weeks before papers appear in a specific issue. Papers published online are definitive and may be altered only through the publication of an Addendum, Author Correction or Publisher Correction, so authors should make every effort to ensure that the page proofs are correct.
Nature Cancer publishes a range of content types including original research articles, and also News & Views, Reviews, Perspectives, Comments, Features and Correspondence that elaborate on significant advances and topical issues in the field.
About the Editors
Like the other Nature titles, Nature Cancer has no external editorial board. Instead, all editorial decisions are made by a dedicated team of full-time professional editors with relevant research and editorial backgrounds. For more information, see About the Editors.
General editorial inquiries and questions about manuscript submission or status should be addressed to firstname.lastname@example.org.
To inquire about institutional access, advertising or marketing, please contact the appropriate department.
Relationship to other Nature journals
Nature Cancer is editorially independent; its editors make their own decisions, independently of the other Nature journals. If a paper is rejected from one Nature journal, the authors can use an automated manuscript transfer service to submit the paper to Nature Cancer via a link sent to them by the editor handling the manuscript. Authors should note that referees' comments (including any confidential comments to the editor) and identities are transferred to the editor of the second journal along with the manuscript. The journal editors will take the previous reviews into account when making their decision, although in some cases the editors may choose to take advice from additional or alternative referees. Alternatively, authors may choose to request a fresh review, in which case they should not use the automated transfer link, and the editors will evaluate the paper without reference to the previous review process. More details are available on the manuscript transfer service and on the relationships between Nature titles.
For papers that could satisfy the scope of more than one Nature journal, the choice of which journal to submit to lies with the authors. For more information, please see the listing of all NPG journals and subject areas.
The correct abbreviation for abstracting and indexing purposes is Nat. Cancer.
The electronic international standard serial number (EISSN) for Nature Cancer is 2662-1347.